

2014

Annual Update in Intensive Care and Emergency Medicine 2014

Edited by J.-L. Vincent

 Springer

Jean-Louis Vincent
Editor

Annual Update in Intensive Care and Emergency Medicine 2014



Editor

Prof. Jean-Louis Vincent
Erasme Hospital
Université libre de Bruxelles
Brussels, Belgium
jlvincen@ulb.ac.be

ISSN 2191-5709

ISBN 978-3-319-03745-5

ISBN 978-3-319-03746-2 (eBook)

DOI 10.1007/978-3-319-03746-2

Springer Cham Heidelberg New York Dordrecht London

© Springer International Publishing Switzerland 2014

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Cover design: WMXDesign GmbH, Heidelberg

Printed on acid-free paper

Springer is part of Springer Science+Business Media
www.springer.com

Annual Update in Intensive Care and Emergency Medicine 2014

The series *Annual Update in Intensive Care and Emergency Medicine* is the continuation of the series entitled *Yearbook of Intensive Care Medicine* in Europe and *Intensive Care Medicine: Annual Update* in the United States.

Common Abbreviations

ALI	Acute lung injury
ARDS	Acute respiratory distress syndrome
BAL	Bronchoalveolar lavage
COPD	Chronic obstructive pulmonary disease
CPAP	Continuous positive airway pressure
CPB	Cardiopulmonary bypass
CT	Computed tomography
CVP	Central venous pressure
DO ₂	Oxygen delivery
EKG	Electrocardiogram
EVLW	Extravascular lung water
FiO ₂	Inspired fraction of oxygen
GEDV	Global end-diastolic volume
ICU	Intensive care unit
IL	Interleukin
LV	Left ventricular
MAP	Mean arterial pressure
MRI	Magnetic resonance imaging
NF- κ B	Nuclear factor kappa-B
NO	Nitric oxide
OR	Odds ratio
PAC	Pulmonary artery catheter
PAOP	Pulmonary artery occlusion pressure
PEEP	Positive end-expiratory pressure
PET	Positron emission tomography
RBC	Red blood cell
RCT	Randomized controlled trial
ROS	Reactive oxygen species
RRT	Renal replacement therapy
RV	Right ventricular
ScvO ₂	Central venous oxygen saturation
SIRS	Systemic inflammatory response syndrome
SOFA	Sequential organ failure assessment
TNF	Tumor necrosis factor
VAP	Ventilator-associated pneumonia
VILI	Ventilator-induced lung injury
V _T	Tidal volume

Contents

Common Abbreviations xi

Part I Infections and Sepsis

Fever Management in Intensive Care Patients with Infections 3
P. Young and M. Saxena

Review on Iron, Immunity and Intensive Care 17
L. T. van Eijk, D. W. Swinkels, and P. Pickkers

Sepsis Guideline Implementation: Benefits, Pitfalls and Possible Solutions 31
N. Kissoon

Antimicrobial Dosing during Extracorporeal Membrane Oxygenation . . 43
P. M. Honoré, R. Jacobs, and H.D. Spapen

**Corticosteroids as Adjunctive Treatment in Community-Acquired
Pneumonia 53**
O. Sibila, M. Ferrer, and A. Torres

Ventilator-associated Pneumonia in the ICU 65
A. A. Kalanuria, M. Mirski, and W. Ziai

Part II Optimal Oxygen Therapy

A Re-evaluation of Oxygen Therapy and Hyperoxemia in Critical Care . 81
S. Suzuki, G. M. Eastwood, and R. Bellomo

Normoxia and Hyperoxia in Neuroprotection 93
P. Le Roux

Part III Mechanical Ventilation

Intubation in the ICU: We Could Improve our Practice	107
A. De Jong, B. Jung, and S. Jaber	
Oral Care in Intubated Patients: Necessities and Controversies	119
S. Labeau and S. Blot	
Sleep and Mechanical Ventilation in Critically Ill Patients	133
C. Psarologakis, S. Kokkini, and D. Georgopoulos	
The Importance of Weaning for Successful Treatment of Respiratory Failure	147
J. Bickenbach, C. Brülls, and G. Marx	

Part IV Lung Protective Strategies

Protective Lung Ventilation During General Anesthesia: Is There Any Evidence?	159
S. Coppola, S. Froio, and D. Chiumello	
Protective Mechanical Ventilation in the Non-injured Lung: Review and Meta-analysis	173
Y. Sutherasan, M. Vargas, and P. Pelosi	
Dynamics of Regional Lung Inflammation: New Questions and Answers Using PET	193
J. Batista Borges, G. Hedenstierna, and F. Suarez-Sipmann	
Non-conventional Modes of Ventilation in Patients with ARDS	207
L. Morales Quinteros and N. D. Ferguson	

Part V Acute Respiratory Distress Syndrome

ARDS: A Clinical Syndrome or a Pathological Entity?	219
P. Cardinal-Fernández, A. Ballén Barragán, and J. A. Lorente	
Novel Pharmacologic Approaches for the Treatment of ARDS	231
R. Herrero, Y. Rojas, and A. Esteban	
Outcome of Patients with Acute Respiratory Distress Syndrome: Causes of Death, Survival Rates and Long-term Implications	245
M. Zambon, G. Monti, and G. Landoni	

Part VI Pulmonary Edema

- Quantitative Evaluation of Pulmonary Edema** 257
 T. Tagami, S. Kushimoto, and H. Yokota
- Distinguishing Between Cardiogenic and Increased Permeability
 Pulmonary Edema** 269
 O. Hamzaoui, X. Monnet, and J.-L. Teboul

Part VII Early Goal-directed Therapy and Hemodynamic Optimization

- Extravascular Lung Water as a Target for Goal-directed Therapy** 285
 M. Y. Kirov, V. V. Kuzkov, and L. J. Bjertnaes
- Real-life Implementation of Perioperative Hemodynamic Optimization** . 299
 M. Biais, A. Senagore, and F. Michard
- Update on Perioperative Hemodynamic Monitoring
 and Goal-directed Optimization Concepts** 309
 V. Mezger, M. Habicher, and M. Sander
- Macro- and Microcirculation in Systemic Inflammation:
 An Approach to Close the Circle** 325
 B. Saugel, C. J. Trepte, and D. A. Reuter

Part VIII Monitoring

- Cardiac Ultrasound and Doppler in Critically Ill Patients:
 Does it Improve Outcome?** 343
 J. Poelaert and P. Flamée
- The Hemodynamic Puzzle: Solving the Impossible?** 355
 K. Tánczos, M. Németh, and Z. Molnár
- A New Generation Computer-controlled Imaging Sensor-based Hand-held
 Microscope for Quantifying Bedside Microcirculatory Alterations** . 367
 G. Aykut, Y. Ince, and C. Ince

Part IX Fluid Therapy

- Pulse Pressure Variation in the Management of Fluids
 in Critically Ill Patients** 385
 A. Messina and P. Navalesi

Albumin: Therapeutic Role in the Current Era	395
A. Farrugia and M. Bansal	

Part X Cardiac Concerns

Inotropic Support in the Treatment of Septic Myocardial Dysfunction: Pathophysiological Implications Supporting the Use of Levosimendan	407
A. Morelli, M. Passariello, and M. Singer	

Supraventricular Dysrhythmias in the Critically Ill: Diagnostic and Prognostic Implications	421
E. Brotfain, M. Klein, and J. C. Marshall	

The Pros and Cons of Epinephrine in Cardiac Arrest	433
J. Rivers and J. P. Nolan	

Part XI Ischemic Brain Damage

Preventing Ischemic Brain Injury after Sudden Cardiac Arrest Using NO Inhalation	449
K. Kida and F. Ichinose	

Neurological Prognostication After Cardiac Arrest in the Era of Hypothermia	461
C. Sandroni, S. D'Arrigo, and M. Antonelli	

Part XII Gastrointestinal Problems

Stress Ulceration: Prevalence, Pathology and Association with Adverse Outcomes	473
M. P. Plummer, A. Reintam Blaser, and A. M. Deane	

Surgical Complications Following Bariatric Surgery	487
P. Montravers, P. Fournier, and P. Augustin	

Acute Liver Failure	503
L. A. Possamai and J. A. Wendon	

Part XIII Renal Issues

**Lung/Kidney Interactions: From Experimental Evidence
to Clinical Uncertainty** 529
D. Schnell, F. Vincent, and M. Darmon

Shifting Paradigms in Acute Kidney Injury 541
W. De Corte, I. De Laet, and E.A.J. Hoste

Part XIV Coagulation and Bleeding

Early Identification of Occult Bleeding Through Hypovolemia Detection 555
A. L. Holder, G. Clermont, and M. R. Pinsky

**Optimizing Intensity and Duration of Oral Antithrombotic Therapy
after Primary Percutaneous Coronary Intervention** 569
G. Biondi-Zoccai, E. Romagnoli, and G. Frati

**The Utility of Thromboelastometry (ROTEM)
or Thromboelastography (TEG) in Non-bleeding ICU Patients . . .** 583
K. Balvers, M.C. Muller, and N.P. Juffermans

Part XV Electrolyte and Metabolic Disorders and Nutrition

Sodium in Critical Illness: An Overview 595
Y. Sakr, C. Santos, and S. Rother

Continuous Glucose Monitoring Devices for Use in the ICU 613
R. T. M. van Hooijdonk, J. H. Leopold, and M. J. Schultz

Nutritional Therapy in the Hospitalized Patient: Is it better to Feed Less? 627
S. A. McClave

Glutamine Supplementation to Critically Ill Patients? 639
J. Wernerman

Part XVI Sedation

Early Goal-directed Sedation in Mechanically Ventilated Patients 651
Y. Shehabi, R. Bellomo, and S. Kadiman

**Assessment of Patient Comfort During Palliative Sedation:
Is it always Reliable?** 663
R. Deschepper, J. Bilsen, and S. Laureys

Part XVII ICU Organization and Quality Issues

Patient Identification, A Review of the Use of Biometrics in the ICU	679
M. Jonas, S. Solangasenathirajan, and D. Hett	
Structured Approach to Early Recognition and Treatment of Acute Critical Illness	689
O. Kilickaya, B. Bonneton, and O. Gajic	
Improving Multidisciplinary Care in the ICU	705
D. M. Kelly and J. M. Kahn	
The Role of Autopsy in Critically Ill Patients	715
G. Berlot, R. Bussani, and D. Cappelli	
Moral Distress in the ICU	723
C. R. Bruce, S. Weinzimmer, and J. L. Zimmerman	
Specific Diagnoses of Organizational Dysfunction to Guide Mechanism- based Quality Improvement Interventions	735
T. J. Iwashyna and A. C. Kajdacsy-Balla Amaral	

Part XVIII Moving Forward...

Where to Next in Combat Casualty Care Research?	747
A. M. Pritchard, A. R. Higgs, and M. C. Reade	
Intensive Care “Sans Frontières”	765
K. Hillman, J. Chen, and J. Braithwaite	
Is Pharmacological, H₂S-induced ‘Suspended Animation’ Feasible in the ICU?	775
P. Asfar, E. Calzia, and P. Radermacher	
Index	789

Part I
Infections and Sepsis

Fever Management in Intensive Care Patients with Infections

P. Young and M. Saxena

Introduction

‘Humanity has but three great enemies: fever, famine and war; of these by far the greatest, by far the most terrible, is fever’ [1].

Fever is one of the cardinal signs of infection and, nearly 120 years after William Osler’s statement in his address to the 47th annual meeting of the American Medical Association [1], infectious diseases remain a major cause of morbidity and mortality. Despite this, it is unclear whether fever itself is truly the enemy or whether, in fact, the febrile response represents an important means to help the body fight infection. Furthermore, it is unclear whether the administration of antipyretic medications or physical cooling measures to patients with fever and infection is beneficial or harmful [2, 3]. Here, we review the biology of fever, the significance of the febrile response in animals and humans, and the current evidence-base regarding the utility of treating fever in intensive care patients with infectious diseases.

The Biology of Fever

Regulation of Normal Body Temperature

Thermoregulation is a fundamental homeostatic mechanism that maintains body temperature within a tightly regulated range. The ability to internally regulate body temperature is known as endothermy and is a characteristic of all mammals and birds. The thermoregulatory system consists of an afferent sensory limb, a central

P. Young ✉

Intensive Care Unit, Wellington Regional Hospital, Wellington, New Zealand
e-mail: paul.young@ccdhb.org.nz

M. Saxena

Department of Intensive Care Medicine, St. George Hospital, Kogarah, Australia

processing center, and an efferent response limb. In humans, the central processing center controlling the thermoregulatory set-point is the hypothalamus. Both warm-sensitive and cold-sensitive thermoreceptors are involved in the afferent limb. Stimulation of the cold-sensitive receptors activates efferent responses relayed via the hypothalamus that reduce heat loss and increase heat production. These responses include reducing blood flow to the peripheries and increasing heat production by mechanisms including shivering. Conversely, stimulation of warm-sensitive receptors ultimately increases heat loss through peripheral vasodilation and evaporative cooling caused by sweating.

The Cellular and Molecular Basis of the Febrile Response

Upward adjustment of the normal hypothalamic thermoregulatory set-point leading to fever is typically part of a cytokine-mediated systemic inflammatory response syndrome that can be triggered by various infectious etiologies including bacterial, viral, and parasitic infections as well as by a range of non-infectious etiologies including severe pancreatitis and major surgery.

In patients with sepsis, the febrile response involves innate immune system activation via Toll-like receptor 4 (TLR-4). This activation leads to production of pyrogenic cytokines including interleukin (IL)-1 β , IL-6, and tumor necrosis factor (TNF)- α . These pyrogenic cytokines act on an area of the brain known as the organum vasculosum of the laminae terminalis (OVLT) leading to the release of prostaglandin E₂ (PGE₂) via activation of the enzyme cyclo-oxygenase-2 (COX-2). PGE₂ binds to receptors in the hypothalamus leading to an increase in heat production and a decrease in heat loss until the temperature in the hypothalamus reaches a new, elevated, set-point. Once the new set-point is attained, the hypothalamus maintains homeostasis around this new set-point by the same mechanisms involved in the regulation of normal body temperature. However, in addition, there are a number of important specific negative feedback systems in place that prevent excessive elevation of body temperature. One key system is the glucocorticoid system, which acts via nuclear factor-kappa B (NF- κ B) and activator protein-1 (AP-1). Both these mediators have anti-inflammatory properties and downregulate the production of pyrogenic cytokines, such as IL-1 β , IL-6, and TNF- α . The febrile response is further modulated by specific antipyretic cytokines including IL-1 receptor antagonist (IL-1RA), IL-10, and TNF- α binding protein.

Heat Shock Proteins and the Febrile Response

The negative feedback systems outlined above are not the only mechanisms that exist to protect cells from being damaged by the febrile response. In addition, the heat shock proteins (HSPs) provide intrinsic resistance to thermal damage. Genes encoding the HSPs probably first evolved more than 2.5 billion years ago. They

represent an important system providing protection to cells, not only against extremes of temperature, but also against other potentially lethal stresses including toxic chemicals and radiation injury. During heat-stress, transcription and translation of HSPs is upregulated. HSPs can then trigger refolding of heat-damaged proteins preserving them until heat-stress has passed or, if necessary, can transport denatured proteins to organelles for intracellular degradation. As well as providing protection against cellular damage from the thermal stress induced by fever, the HSPs may themselves be important regulators of the febrile response. For example, HSP 70 inhibits pyrogenic cytokine production via NF- κ B. HSPs also inhibit programmed cell death, which might otherwise be induced by an invading pathogen.

The Physiological Consequences of Fever

The febrile response leads to a marked increase in metabolic rate. In humans, generating fever through shivering increases the metabolic rate above basal levels by six-fold [4]. In critically ill patients with fever, cooling reduces oxygen consumption by about 10 % per °C decrease in core temperature and significantly reduces cardiac output and minute ventilation [5]. Any potential benefit of the febrile response needs to be weighed against this substantial metabolic cost.

The Immunological Consequences of Fever

Temperatures in the physiological febrile range stimulate the maturation of murine dendritic cells. This is potentially important because dendritic cells act as the key antigen presenting cells in the immune system. Human neutrophil cell motility and phagocytosis are enhanced by temperatures in the febrile range, and growth of intracellular bacteria in human macrophages *in vitro* is reduced by temperatures in the febrile range compared to normal temperatures. Murine macrophages demonstrate a range of enhanced functions at temperatures in the febrile range. These effects include enhanced expression of the Fc receptors that are involved in mediating antibody responses, and enhanced phagocytosis. Temperatures in the physiological febrile range enhance binding of human lymphocytes to the vascular endothelium. This L-selectin-mediated binding is important in facilitating lymphocyte migration to sites of tissue inflammation or infection. In mice, T lymphocyte-mediated killing of virus-infected cells is increased by temperatures in the febrile range and helper T-cell potentiation of antibody responses is enhanced. In contrast to other cells of the immune system, the cytotoxic activity of natural killer cells is reduced by temperatures in the febrile range compared to normal body temperature. Although their functions are enhanced by temperatures in the physiological febrile range (38–40 °C), neutrophils and macrophages have substantially reduced function at temperatures of ≥ 41 °C.